In a phase 1b trial, the authors explored the safety, tolerability, and efficacy of combining the anti-PD-1 monoclonal antibody nivolumab with the IL-15 superagonist ALT-803 in patients with previously treated NSCLC (185). Here, PDCD1 is linked to non-small cell lung carcinoma.